Developing live vaccines against Yersinia pestis

Journal of Infection in Developing Countries

Volumn 5, Issue 9, 2011, Pages 614-627

  Sun, Wei ^a   Roland, Kenneth L ^a   Curtiss III, Roy ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Live vaccines; Plague; Yersinia pestis

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VECTOR; BCG VACCINE; CHICKENPOX VACCINE; CHOLERA VACCINE; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; MUMPS VACCINE; PLAGUE VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RECOMBINANT VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; SALMONELLOSIS VACCINE; SUBUNIT VACCINE; TYPHOID VACCINE; VIRULENCE FACTOR; VIRUS VECTOR; YELLOW FEVER VACCINE;

ADENOVIRUS; BACTERIAL GENE; BACTERIUM MUTANT; CELLULAR IMMUNITY; CHICKENPOX; CHOLERA; CYTOMEGALOVIRUS INFECTION; GENE TRANSFER; HERPES VIRUS INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; LISTERIA MONOCYTOGENES; MEASLES; MUCOSAL IMMUNITY; MUMPS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLAGUE; POLIOMYELITIS; POXVIRUS; RABIES; REVIEW; ROTAVIRUS INFECTION; RUBELLA; TUBERCULOSIS; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; YELLOW FEVER; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

NEGIBACTERIA; SALMONELLA; YERSINIA PESTIS;

EID: 80052923060     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.2030     Document Type: Review

References (144)

1. Shih C-L and SF-Y (2002) Plague in bioterrorism. Ann Disaster Med 1: S26-35.
2. Perry RD and Fetherston JD (1997) Yersinia pestis- etiologic agent of plague. Clinical microbiology reviews 10: 35-66.
3. Human plague in 2000 and 2001 (2003) Wkly Epidemiol Rec 78: 130-135.
4. Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, Carniel E, Gage KL, Leirs H, Rahalison L (2008) Plague: past, present, and future. PLoS Med 5, e3.
5. Butler T (1983) Plague and other Yersinia infections, New York: Plenum Press, 220 p.
6. Straley SC and Starnbach MN (2000) Yersinia: Strategies that thwart immune defenses in Cunningham MW and Fujinami RS, editors. Effects of Microbes on the Immune System. Philadelphia: Lippincott Williams & Wilkins. 71-92.
7. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K; Working Group on Civilian Biodefense (2000) Plague as a biological weapon: medical and public health management. JAMA 283: 2281-2290.
8. Atlas RM (1998) The medical threat of biological weapons. Critical reviews in microbiology 24: 157-168.
9. Danzig R and Berkowsky PB (1997) Why should we be concerned about biological warfare? JAMA 278: 431-432.
10. Henderson DA (1998) Bioterrorism as a public health threat. Emerging infectious diseases 4: 488-492.
11. Inglesby TV, Henderson DA, O'Toole T, Dennis DT (2000) Safety precautions to limit exposure from plague-infected patients. JAMA 284: 1648-1649.
12. Guiyoule A, Rasoamanana B, Buchrieser C, Michel P, Chanteau S, Carniel E (1997) Recent emergence of new variants of Yersinia pestis in Madagascar. J Clin Microbiol 35: 2826-2833.
13. Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, Courvalin P, Carniel E (2001) Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 7: 43-48.
14. Smiley ST (2008) Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 7: 209-221.
15. Feodorova VA and Corbel MJ (2009) Prospects for new plague vaccines. Expert Rev Vaccines 8: 1721-1738.
16. Quenee LE and Schneewind O (2009) Plague vaccines and the molecular basis of immunity against Yersinia pestis. Hum Vaccin 5: 817-823
17. Titball RW and Williamson ED (2004) Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4, 965-973.
18. Smiley ST (2008) Immune defense against pneumonic plague. Immunol Rev 225: 256-271.
19. Giudice EL and Campbell JD (2006) Needle-free vaccine delivery. Adv Drug Deliv Rev 58: 68-89.
20. Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD, Lechuga-Ballesteros D, Truong-Le V (2010) Heat-stable measles vaccine produced by spray drying. Vaccine 28: 1275-1284.
21. Ohtake S, Martin R, Saxena A, Pham B, Chiueh G, Osorio M, Kopecko D, Xu D, Lechuga-Ballesteros D, Truong-Le V (2011) Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 29: 2761-2771.
22. Jones SM, Griffin KF, Hodgson I, Williamson ED (2003) Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21: 3912-3918.
23. Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW (1995) A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13: 1551-1556.
24. Meyer KF (1970) Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 42: 653-666.
25. Cavanaugh DC, Elisberg BL, Llewellyn CH, Marshall JD, Jr., Rust JH, Jr., Williams JE and Meyer KF (1974) Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 129, Suppl: S37-40.
26. Meyer KF, Cavanaugh DC, Bartelloni PJ, Marshall JD, Jr. (1974) Plague immunization. I. Past and present trends. J Infect Dis 129, Suppl: S13-18.
27. Cohen RJ and Stockard JL (1967) Pneumonic plague in an untreated plague-vaccinated individual. JAMA 202: 365-366.
28. Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, Ciletti NA, Schneewind O (2008) Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 76: 5588-5597.
29. Williamson ED, Flick-Smith HC, Waters E, Miller J, Hodgson I, Le Butt CS, Hill J (2007) Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb Pathog 42: 11-21.
30. Alvarez ML, Pinyerd HL, Crisantes JD, Rigano MM, Pinkhasov J, Walmsley AM, Mason HS, Cardineau GA (2006) Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine 24: 2477-2490.
31. Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C, Worsham P, Pullen JK, Ribot W, Hines H, Smith L, Heath DG, Adamovicz JJ (2005) Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21: 1490-1510.
32. Badgett MR, Auer A, Carmichael LE, Parrish CR, Bull JJ (2002) Evolutionary dynamics of viral attenuation. J Virol 76: 10524-10529.
33. Behr MA (2002) BCG-different strains, different vaccines? Lancet Infect Dis 2: 86-92.
34. th Edition, Philadelphia: Mosby Elsevier 552 p.
35. National Network for immunization Information (2010) Rabies Available: www.immunizationinfo.org/vaccines/rabies. Accessed 29 August 2011.
36. Modlin JF (2004) Poliomyelitis in the United States: the final chapter? JAMA 292: 1749-1751.
37. Levine MM (2000) Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr 31: 336-355.
38. Kapikian AZ, Hoshino Y, Chanock RM and Perez-Schael I (1996) Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 174 Suppl 1: S65-72.
39. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC (2007) Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 45 Suppl 1: S24-28.
40. Minne A, Jaworska J, Gerhold K, Ahrens B, Avagyan A, Vanbever R, Matricardi PM, Schmidt AC, Hamelmann E (2007) Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice. Clin Exp Allergy 37: 1250-1258.
41. Lin K (2007) Intranasal influenza vaccine may be a safe, effective option for many children. J Pediatr 151: 102-103.
42. CDC (2009) H1N1 Clinicians Questions and Answers. Recommendations for the 2009 H1N1 Vaccine. http://www.cdc.gov/h1n1flu/vaccination/clinicians_qa.htm Accessed October 2009.
43. Medina E and Guzman CA (2000) Modulation of immune responses following antigen administration by mucosal route. FEMS Immunol Med Microbiol 27: 305-311.
44. Neutra MR and Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
45. Garmory HS, Leary SE, Griffin KF, Williamson ED, Brown KA, Titball RW (2003) The use of live attenuated bacteria as a delivery system for heterologous antigens. J Drug Target 11: 471-479.
46. Atkins HS, Morton M, Griffin KF, Stokes MG, Nataro JP, Titball RW (2006) Recombinant Salmonella vaccines for biodefence. Vaccine 24: 2710-2717.
47. Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication- defective adenovirus vectors. Nature Medicine 2: 545-550.
48. Wilson JM (1996) Adenoviruses as gene-delivery vehicles. N Engl J Med 334: 1185-1187.
49. Boyer JL, Kobinger G, Wilson JM, Crystal RG (2005) Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 16: 157-168.
50. Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG (2006) Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 194: 1249-1257.
51. Boyer JL, Sofer-Podesta C, Ang J, Hackett NR, Chiuchiolo MJ, Senina S, Perlin D, Crystal RG (2010) Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum Gene Ther 21: 891-901.
52. Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK (2007) An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 25: 741-750.
53. Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK (2008) Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 26: 6329-6337.
54. Brewooa JN, Powell T D, Stinchcomb DT, Osorio JE (2010) Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine 28: 5891-5899.
55. Bhattacharya D, Mecsas J, Hu LT (2010) Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis. Vaccine 28: 7683-7689.
56. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HWt (2007) Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447: 326-329.
57. Osorio JE, Powell TD, Frank RS, Moss K, Haanes EJ, Smith SR, Rocke TE, Stinchcomb DT (2003) Recombinant raccoon pox vaccine protects mice against lethal plague. Vaccine 21: 1232-1238.
58. Mencher JS, Smith SR, Powell TD, Stinchcomb DT, Osorio JE, Rocke TE (2004) Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine. Infect Immun 72:5502-5505.
59. Rocke TE, Smith SR, Stinchcomb DT, Osorio JE (2008) Immunization of black-tailed prairie dog against plague through consumption of vaccine-laden baits. J Wildl Dis 44: 930-937.
60. Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, Pasetti MF Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol 3: 159-171.
61. Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B, Simonet M, Daniel C (2007) Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 133: 862-874.
62. Carter PB and Collins FM (1974) The route of enteric infection in normal mice. J Exp Med 139: 1189-1203.
63. Giannasca PJ and Neutra MR (1993) Interactions of microorganisms with intestinal M cells: mucosal invasion and induction of secretory immunity. Infect Agents Dis 2: 242-248.
64. Nix RN, Altschuler SE, Henson PM, Detweiler CS (2007) Hemophagocytic macrophages harbor Salmonella enterica during persistent infection. PLoS Pathog 3: e193.
65. Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW (1997) Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb Pathog 23: 167-179.
66. Garmory HS, Griffin KF, Brown KA, Titball RW (2003) Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine 21: 3051-3057.
67. Titball RW, Howells AM, Oyston PC, Williamson ED (1997) Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 65: 1926-1930.
68. Yang X, Hinnebusch BJ, Trunkle T, Bosio CM, Suo Z, Tighe M, Harmsen A, Becker T, Crist K, Walters N, Avci R, Pascual DW (2007) Oral vaccination with Salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol 178: 1059-1067.
69. Branger CG, Fetherston JD, Perry RD, Curtiss R, III (2007) Oral vaccination with different antigens from Yersinia pestis KIM delivered by live attenuated Salmonella typhimurium elicits a protective immune response against plague. Adv Exp Med Biol 603: 387-399.
70. Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, Curtiss R, III (2010) Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge. Vaccine 29: 274-282.
71. Morton M, Garmory HS, Perkins SD, O'Dowd AM, Griffin KF, Turner AK, Bennett AM, Titball RW (2004) A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine 22: 2524-2532.
72. Ramirez K, Capozzo AV, Lloyd SA, Sztein MB, Nataro JP, Pasetti MF (2009) Mucosally delivered Salmonella Typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. J Immunol 182: 1211-1222.
73. Williams JE and Cavanaugh DC (1983) Chronic infections in laboratory rodents from inoculation of nonencapsulated plague bacilli (Yersinia pestis). Experientia 39: 408-409.
74. Williams JE and Cavanaugh DC (1984) Potential for rat plague from nonencapsulated variants of the plague bacillus (Yersinia pestis). Experientia 40, 739-740.
75. Weening EH, Cathelyn JS, Kaufman G, Lawrenz MB, Price P, Goldman WE, Miller VL (2011) The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background. Infect Immun 79: 644-652.
76. Winter CC, Cherry WB, Moody MD (1960) An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull World Health Organ 23: 408-409.
77. Anisimov AP, Dentovskaya SV, Panfertsev EA, Svetoch TE, Kopylov PK, Segelke BW, Zemla A, Telepnev MV, Motin VL (2009) Amino acid and structural variability of Yersinia pestis LcrV protein. Infect Genet Evol 10: 137-145.
78. Ben-Efraim S, Aronson M, Bichowsky-Slomnicki L (1961) New antigen component of Pasteurella pestis formed under specified conditions of pH and temperature. J Bacteriol 81: 704-714.
79. Torres-Escobar A, Juarez-Rodriguez MD, Branger CG, Curtiss R, III (2010) Evaluation of the humoral immune response in mice orally vaccinated with live recombinant attenuated Salmonella enterica delivering a secreted form of Yersinia pestis PsaA. Vaccine 28: 5810-5816.
80. Fetherston JD, Lillard JW Jr, Perry RD (1995) Analysis of the pesticin receptor from Yersinia pestis: role in iron- deficient growth and possible regulation by its siderophore. J Bacteriol 177: 1824-1833.
81. Hornung JM, Jones HA, Perry RD (1996) The hmu locus of Yersinia pestis is essential for utilization of free haemin and haem-protein complexes as iron sources. Mol Microbiol 20: 725-739.
82. Lindler LE, Klempner MS, Straley SC (1990) Yersinia pestis pH 6 antigen: genetic, biochemical, and virulence characterization of a protein involved in the pathogenesis of bubonic plague. Infect Immun 58: 2569-2577.
83. Anisimov AP, Bakhteeva IV, Panfertsev EA, Svetoch TE, Kravchenko TB, Platonov ME, Titareva GM, Kombarova TI, Ivanov SA, Rakin AV, Amoako KK, Dentovskaya SV (2009) The subcutaneous inoculation of pH 6 antigen mutants of Yersinia pestis does not affect virulence and immune response in mice. J Med Microbiol 58: 26-36.
84. Cathelyn JS, Crosby SD, Lathem WW, Goldman WE, Miller VL (2006) RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague. Proc Natl Acad Sci USA 103: 13514-13519.
85. Yang Y, Merriam JJ, Mueller JP, Isberg RR (1996) The psa locus is responsible for thermoinducible binding of Yersinia pseudotuberculosis to cultured cells. Infect Immun 64: 2483-2489.
86. Huang XZ and Lindler LE (2004) The pH 6 antigen is an antiphagocytic factor produced by Yersinia pestis independent of Yersinia outer proteins and capsule antigen. Infect Immun 72: 7212-7219.
87. Jackson S and Burrows TW (1956) The virulence-enhancing effect of iron on non-pigmented mutants of virulent strains of Pasteurella pestis. Br J Exp Pathol 37: 577-583.
88. Girard G (1963) Immunity in plague. Acquisitions supplied by 30 years of work ont the Pasteurella pestis EV (Girard and Robic) strain. Biol Med (Paris) 52: 631-731.
89. Saltykova RA and Faibich MM (1975) Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR. Zh Mikrobiol Epidemiol Immunobiol, 6: 3-8.
90. Meyer KF, Smith G, Foster L, Brookman M, Sung M (1974) Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J Infect Dis 129, Suppl: S85-120.
91. Hallett AF, Isaacson M, Meyer KF (1973) Pathogenicity and immunogenic efficacy of a live attentuated plaque vaccine in vervet monkeys. Infect Immun 8: 876-881.
92. Une T and Brubaker RR (1984) In vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae. Infect Immun 43: 895-900.
93. (1970) WHO Expert Committee on Plague. WHO Tech Rep Ser 447: 16.
94. Hohmann EL, Oletta CA, Miller SI (1996) Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14: 19-24.
95. O'Callaghan D, Maskell D, Liew FY, Easmon CS and Dougan G (1988) Characterization of aromatic- and purine- dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun 56: 419-423.
96. Dougan G (1994) 1993 Colworth Prize Lecture. The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development. Microbiology 140 (Pt 2): 215-224.
97. Oyston PC, Russell P, Williamson ED, Titball RW (1996) An aroA mutant of Yersinia pestis is attenuated in guinea- pigs, but virulent in mice. Microbiology 142 (Pt 7): 1847-1853.
98. Oyston PC, Dorrell N, Williams K, Li SR, Green M, Titball RW, Wren BW (2000) The response regulator PhoP is important for survival under conditions of macrophage- induced stress and virulence in Yersinia pestis. Infect Immun 68: 3419-3425.
99. Williams K, Oyston PC, Dorrell N, Li S, Titball RW, Wren BW (2000) Investigation into the role of the serine protease HtrA in Yersinia pestis pathogenesis. FEMS Microbiol Lett 186: 281-286.
100. Sha J, Agar SL, Baze WB, Olano JP, Fadl AA, Erova TE, Wang S, Foltz SM, Suarez G, Motin VL, Chauhan S, Klimpel GR, Peterson JW, Chopra AK (2008) Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun 76: 1390-1409.
101. Pizarro-Cerda J and Tedin K (2004) The bacterial signal molecule, ppGpp, regulates Salmonella virulence gene expression. Mol Microbiol 52: 1827-1844.
102. Curtiss R, III and Kelly SM (1987) Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun 55: 3035-3043.
103. Zhan L, Han Y, Yang L, Geng J, Li Y, Gao H, Guo Z, Fan W, Li G, Zhang L, Qin C, Zhou D, Yang R (2008) The cyclic AMP receptor protein, CRP, is required for both virulence and expression of the minimal CRP regulon in Yersinia pestis biovar microtus. Infect Immun 76: 5028-5037.
104. Sun W, Roland KL, Branger CG, Kuang X and Curtiss R, III (2009) The role of relA and spoT in Yersinia pestis KIM5+ pathogenicity. PLoS One 4: e6720.
105. Sun W, Roland KL, Kuang X, Branger CG, Curtiss R, III (2010) Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. Infect Immun 78: 1304-1313.
106. Curtiss R, III, Wanda SY, Gunn BM, Zhang X, Tinge SA, Ananthnarayan V, Mo H, Wang S, Kong W (2009) Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect Immun 77: 1071-1082.
107. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B (2000) Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci U S A 97: 2163-2167.
108. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162: 3749-3752.
109. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT (2000) Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105: 497-504.
110. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 282: 2085-2088.
111. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, Conlon JE, Fukase K, Kusumoto S, Sweet C, Miyake K, Akira S, Cotter RJ, Goguen JD, Lien E (2006) Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 7: 1066-1073.
112. Sun W, Six D, Kuang XY, Roland KL, Raetz CRH, Curtiss RIII. (2011) A live attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine 29: 2986-2998.
113. Brubaker RR (2003) Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 71: 3673-3681.
114. Bubeck SS and Dube PH (2007) Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine. Clin Vaccine Immunol 14: 1235-1238.
115. Flashner Y, Mamroud E, Tidhar A, Ber R, Aftalion M, Gur D, Lazar S, Zvi A, Bino T, Ariel N, Velan B, Shafferman A, Cohen S (2004) Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect Immun 72: 908-915.
116. Tidhar A, Flashner Y, Cohen S, Levi Y, Zauberman A, Gur D, Aftalion M, Elhanany E, Zvi A, Shafferman A, Mamroud E (2009) The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS One 4: e7023.
117. Achtman M, Zurth K, Morelli G, Torrea G, Guiyoule A, Carniel E (1999) Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci U S A 96: 14043-14048.
118. Chain PS, Carniel E, Larimer FW, Lamerdin J, Stoutland PO, Regala WM, Georgescu AM, Vergez LM, Land ML, Motin VL, Brubaker RR, Fowler J, Hinnebusch J, Marceau M, Medigue C, Simonet M, Chenal-Francisque V, Souza B, Dacheux D, Elliott JM, Derbise A, Hauser LJ, Garcia E (2004) Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc Natl Acad Sci USA 101: 13826-13831.
119. Taylor VL, Titball RW, Oyston PC (2005) Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology 151: 1919-1926.
120. Blisnick T, Ave P, Huerre M, Carniel E and Demeure CE (2008) Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun 76: 3808-3816.
121. Okan NA, Mena P, Benach JL, Bliska JB, Karzai AW (2010) The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection. Infect Immun 78, 1284-1293.
122. Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M (2005) Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73: 3598-3608.
123. Welkos S, Pitt ML, Martinez M, Friedlander A, Vogel P, Tammariello R (2002) Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine 20: 2206-2214.
124. Keeling MJ and Gilligan CA (2000) Metapopulation dynamics of bubonic plague. Nature 407: 903-906.
125. Bevins SN, Tracey JA, Franklin SP, Schmit VL, Macmillan ML, Gage KL, Schriefer ME, Logan KA, Sweanor LL, Alldredge MW, Krumm C, Boyce WM, Vickers W, Riley SP, Lyren LM, Boydston EE, Fisher RN, Roelke ME, Salman M, Crooks KR, Vandewoude S (2009) Wild felids as hosts for human plague, Western United States. Emerg Infect Dis 15: 2021-2024.
126. Poland JD, Barnes AM, Herman JJ (1973) Human bubonic plague from exposure to a naturally infected wild carnivore. Am J Epidemiol 97: 332-337.
127. Eisen RJ, Petersen JM, Higgins CL, Wong D, Levy CE, Mead PS, Schriefer ME, Griffith KS, Gage KL, Beard CB (2008) Persistence of Yersinia pestis in soil under natural conditions. Emerg Infect Dis 14: 941-943.
128. Griffin KA, Martin DJ, Rosen LE, Sirochman MA, Walsh DP, Wolfe LL, Miller MW (2010) Detection of Yersinia pestis DNA in prairie dog-associated fleas by polymerase chain reaction assay of purified DNA. J Wildl Dis 46: 636-643.
129. Wobeser G, Campbell GD, Dallaire A, McBurney S (2009) Tularemia, plague, yersiniosis, and Tyzzer's disease in wild rodents and lagomorphs in Canada: a review. Can Vet J 50: 1251-1256.
130. Eisen RJ, Holmes JL, Schotthoefer AM, Vetter SM, Montenieri JA, Gage KL (2008) Demonstration of early- phase transmission of Yersinia pestis by the mouse flea, Aetheca wagneri (Siphonaptera: Ceratophylidae), and implications for the role of deer mice as enzootic reservoirs. J Med Entomol 45: 1160-1164.
131. Oyston PC, Williamson ED, Leary SE, Eley SM, Griffin KF, Titball RW (1995) Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun 63: 563-568.
132. Bullifent HL, Griffin KF, Jones SM, Yates A, Harrington L, Titball RW (2000) Antibody responses to Yersinia pestis F1- antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. Vaccine 18: 2668-2676.
133. Garmory HS, Leckenby MW, Griffin KF, Elvin SJ, Taylor RR, Hartley MG, Hanak JA, Williamson ED, Cranenburgh RM (2005) Antibiotic-free plasmid stabilization by operator- repressor titration for vaccine delivery by using live Salmonella enterica serovar Typhimurium. Infect Immun 73: 2005-2011.
134. Liu WT, Hsu HL, Liang CC, Chuang CC, Lin HC, Liu YT (2007) A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen. FEMS Immunol Med Microbiol 51: 58-69.
135. Torres-Escobar A, Juarez-Rodriguez MD, Gunn BM, Branger CG, Tinge SA, Curtiss R III (2010) Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar Typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice. Infect Immun 78: 2529-2543.
136. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SE, Oyston PC, Easterbrook T, Reddin KM, Robinson A, Titball RW (1995) A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12: 223-230.
137. Welkos S and O'Brien A (1994) Determination of median lethal and infectious doses in animal model systems. Methods Enzymol 235: 29-39.
138. Andrews GP, Heath DG, Anderson GW, Jr, Welkos SL, Friedlander AM (1996) Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64: 2180-2187.
139. Lathem WW, Crosby SD, Miller VL, Goldman WE (2005) Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 102: 17786-17791.
140. Agar SL, Sha J, Foltz SM, Erova TE, Walberg KG, Parham TE, Baze WB, Suarez G, Peterson JW, Chopra AK (2008) Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92. Microbiology 154: 1939-1948.
141. Robinson VL, Oyston PC, Titball RW (2005) A dam mutant of Yersinia pestis is attenuated and induces protection against plague. FEMS Microbiol Lett 252: 251-256.
142. Feodorova VA, Pan'kina LN, Savostina EP, Sayapina LV, Motin VL, Dentovskaya SV, Shaikhutdinova RZ, Ivanov SA, Lindner B, Kondakova AN, Bystrova OV, Kocharova NA, Senchenkova SN, Holst O, Pier GB, Knirel YA, Anisimov AP (2007) A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 25: 7620-7628.
143. Oyston PC, Mellado-Sanchez G, Pasetti MF, Nataro JP, Titball RW, Atkins HS (2010) A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection. Microb Pathog 48: 191-195.
144. Feodorova VA and Devdariani ZL (2001) Immunogeneity and structural organisation of some pLCR-encoded proteins of Yersinia pestis. J Med Microbiol 50: 13-22.